Welcome to our dedicated page for ReShape Lifesciences SEC filings (Ticker: RSLS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The RSLS SEC filings archive documents the regulatory history of ReShape Lifesciences Inc. prior to and through its transformation into Vyome Holdings, Inc. These filings, made with the U.S. Securities and Exchange Commission, provide detailed information on the company e2 80 99s weight loss and metabolic health device business, its major strategic transactions, and the subsequent name and ticker change to HIND on The Nasdaq Capital Market.
Key filings include multiple Form 8-K current reports describing material events. Among them are disclosures of the Agreement and Plan of Merger with Vyome Therapeutics, Inc., the closing of the merger on August 15, 2025, and the resulting change of the registrant e2 80 99s name to Vyome Holdings, Inc. They also describe the 1-for-4 reverse stock split of the company e2 80 99s common stock and the continuation of Nasdaq listing under the new trading symbol HIND. Other 8-K filings detail shareholder meeting results, including approvals of share issuances, the asset sale, charter amendments, and reverse split authorization.
The filings further outline the Asset Purchase Agreement with Ninjour Health International Limited, an affiliate of Biorad Medisys Pvt. Ltd., under which ReShape Lifesciences sold substantially all of its assets (excluding cash) and Biorad assumed substantially all of its liabilities. Disclosures specify that the Lap-Band ae System, Obalon ae Gastric Balloon System, and the DBSN ae system were among the assets transferred. Additional 8-K items address financing arrangements, such as an equity distribution agreement for at-the-market offerings, and changes in the company e2 80 99s independent registered public accounting firm.
After the merger, subsequent 8-K and 8-K/A filings under the Vyome Holdings, Inc. name (trading as HIND) provide Vyome e2 80 99s financial statements, management e2 80 99s discussion and analysis, and unaudited pro forma condensed combined financial statements giving effect to the merger. Amendments such as 8-K/A filings correct and update pro forma calculations, ensuring that the combined company e2 80 99s financial presentation is accurate for incorporation into existing shelf registration statements.
On Stock Titan, users can access these RSLS-related SEC filings in one place, with real-time updates pulled from EDGAR. AI-powered summaries help explain the significance of complex documents like 8-K merger reports, reverse stock split disclosures, and pro forma financial statements. Investors can also review historical ownership and governance changes, as reflected in board and executive transitions reported in the filings, and trace how the former ReShape Lifesciences entity evolved into Vyome Holdings, Inc. under the HIND ticker.
Vyome Holdings, Inc. furnished an investor presentation highlighting Phase 2 results for VT-1953, a 2% topical gel for malignant fungating wounds. In a 15-patient investigator-sponsored study, VT-1953 significantly reduced malodor by Day 14 versus baseline (p=0.0020) and versus vehicle (p=0.0015), and improved patient-reported malodor impact on quality of life (p=0.0256). Patients also showed statistically significant reductions in malodor and lesion pain on visual analog scales and better composite quality-of-life scores, while exudate did not materially change. VT-1953 was well tolerated with no treatment-emergent adverse events or local reactions reported. Vyome cites a U.S. market opportunity of about $2.2 billion based on ~58,000 new patients per year and a lifetime value per patient of $55,000, and states it is capitalized to fund operations until Phase 3 interim readouts.
Vyome Holdings, Inc. furnished an investor presentation and a related product assessment report about VT-1953, its lead clinical candidate for treating symptoms of malignant fungating wounds. These materials are provided as Exhibit 99.1 under Regulation FD and are not deemed filed for liability purposes.
The company also reported that it issued a press release on January 27, 2026, summarizing key findings from an independent U.S. market assessment, commercial forecast, and valuation analysis for VT-1953, which is attached as Exhibit 99.2. Both exhibits are incorporated by reference and include forward-looking statements about business strategy, capital needs, market potential, and future operating results.
Vyome Holdings Form 4: This Form 4 reports that Venkat Nelabhotla, President, CEO and a director, received 7 shares of Vyome Holdings common stock as a result of a merger on 08/15/2025. Under the Merger Agreement, each 5,000 shares of Vyome Therapeutics common stock converted into 1 share of Vyome Holdings common stock. The reporting person exchanged 35,000 Vyome Therapeutics shares and received 7 Vyome Holdings shares. The Form 4 was filed as a single reporting person and is signed on 09/22/2025.
John M. Tincoff III filed an initial Form 3 reporting his relationship to Vyome Holdings, Inc. (ticker shown in the filing as HIND) as a Director. The event date is 08/15/2025. The filing states no securities are beneficially owned by the reporting person. The form is signed and dated 09/18/2025.
Vyome Holdings, Inc. filed an amended Form 8-K to correct errors in previously filed pro forma financial information. The company states that Amendment No. 1 is being filed solely to replace Exhibit 99.3 with corrected Unaudited Pro Forma Condensed Combined Financial Statements, now provided as Exhibit 99.1.
No other disclosures from the original September 2, 2025 Form 8-K are modified, and the amendment does not address events occurring after that original filing date.
Robert Dickey IV, Chief Financial Officer and Director of Vyome Holdings, Inc., reported a change in beneficial ownership related to a merger involving Vyome Therapeutics. The reporting person received 762 shares of Vyome Holdings common stock on 08/15/2025 in exchange for 3,810,000 shares of Vyome Therapeutics common stock under the Merger Agreement, which converted every 5,000 Vyome Therapeutics shares into one share of the issuer. The Merger resulted in Vyome Therapeutics becoming a subsidiary of the issuer and the renamed parent company Vyome Holdings, Inc. The Form 4 discloses the acquisition as a non-derivative transaction and indicates the reporting person holds the shares directly.
Venkateswarlu Nelabhotla filed an SEC Form 3 reporting his initial statement of beneficial ownership with respect to Vyome Holdings, Inc. (ticker HIND). The filing, tied to an event dated 08/15/2025, identifies him as both President & CEO and a director. The Form 3 states no securities are beneficially owned by the reporting person. The form is signed and dated 09/11/2025.
Vyome Holdings, Inc. (ticker HIND) filed an Initial Statement of Beneficial Ownership (Form 3) for Robert Dickey IV, who is identified as the company’s Chief Financial Officer and a director. The filing reports the qualifying event date as 08/15/2025 and is signed on 09/11/2025. The form states explicitly that no securities are beneficially owned by the reporting person at the time of filing, meaning Mr. Dickey disclosed no direct or indirect ownership of the issuer’s equity or derivative securities in this submission.
Vyome Holdings, Inc. reported that it has completed its previously announced merger in which Raider Lifesciences Inc., a subsidiary of the company, merged into Vyome Therapeutics, Inc., with Vyome surviving as a subsidiary. Following the merger, the registrant was renamed Vyome Holdings, Inc. and Vyome continues as Vyome Therapeutics, Inc.
The company is providing Vyome’s financial statements for the quarter ended June 30, 2025, Vyome’s Management’s Discussion and Analysis for that quarter, and unaudited pro forma condensed combined financial statements as exhibits. This information is being made available so it can be incorporated by reference into Vyome Holdings’ shelf registration statement on Form S-3.
Vyome Holdings, Inc. reported that it amended its equity distribution agreement with Maxim Group to increase the size of its at-the-market common stock offering capacity from $3,420,926 to $12,000,000, allowing shares to be sold from time to time under its existing Form S-3 shelf registration.
The company also changed its independent registered public accounting firm, dismissing Haskell & White LLP and appointing Kreit & Chiu CPA LLP for the fiscal year ending December 31, 2025, with the change approved by the audit committee and board. Vyome states there were no disagreements with Haskell on accounting or auditing matters, though Haskell’s report for the year ended December 31, 2024 included an explanatory paragraph about substantial doubt regarding Vyome’s ability to continue as a going concern and referenced material weaknesses in internal control over financial reporting.